Biodextris

Biodextris is recognized by biotech city as one of the canadian organizations in the fight against covid-19

The Website Store • April 9, 2020

The Biotech City is proud of the efforts of resident companies contributing to the fight against COVID-19:


Nexelis has been granted reference laboratory status by the Bill and Melinda Gates foundation and is collaborating on candidate vaccines.
Corealis Pharma Inc. has developed oral formulations for antivirals and manufactures clinical batches.
Altasciences has completed a Phase I on gimsilumab in SARS-CoV-2 patients.
Biodextris developing a nasal vaccine platform with preclinical activity.
Roche Diagnostics provides instruments and tests to respond to the pandemic.
Bausch Health donates drugs.
CQIB incubator companies are also involved:
Ovensa Inc. is working on siRNA to modulate viral infection and pulmonary fibrosis.
Oligo Medic has adapted to the manufacture of disinfectant gel.
Glycovax Pharma is working on a platform for viral adhesion inhibitors.
IniXium conducts research on the replication of the virus.
ILS Pharmaceutical performs compliance tests for the release of drugs and disinfectant products.


View original post here: https://www.linkedin.com/posts/cit-de-la-biotech-biotech-city_the-biotech-city-is-proud-of-the-efforts-activity-6651540714033340416-IpzG/

Biodextris - Bringing Innovation to Life

With Biodextris, your project is overseen by dedicated project managers with extensive hands-on experience, saving you time and enhancing your experience.


Learn more about us ➜

Leave A Comment

Search

Recent Posts

By Philippe Beland June 11, 2025
Biodextris Appoints Dr. Behzad Mahdavi as Executive Chairman & Chief Commercial Officer Who: Dr. Behzad Mahdavi, Ph.D., MBA, NACD.DC — a biopharma industry veteran with over 25 years of senior leadership experience in CDMO and CRO sectors, including roles at Lonza and Catalent. What: He has been appointed Executive Chairman and will additionally serve as Chief Commercial Officer at Biodextris. Why: Dr. Mahdavi will spearhead the company’s global commercial expansion, leveraging his expertise in commercial innovation and international market development About Biodextris: Headquartered in Laval (Montréal), Québec, Biodextris is a rising Contract Development & Manufacturing Organization (CDMO) specializing in biologics and vaccine development, rooted in the legacy of GSK’s biologics and supported by ArchiMed private equity. For full details, you can read the original PR Newswire article here: https://www.prnewswire.com/news-releases/biodextris-appoints-dr-behzad-mahdavi-as-executive-chairman-to-lead-global-commercial-expansion-302472664.html
December 17, 2024
Learn about the strategic partnership between Aramis Biotechnologies and Biodextris to advance vaccine and biologics development.
December 17, 2024
Clean Biologics acquires Biodextris—bringing together expertise in biologics manufacturing and accelerating growth in CDMO services.
Biodextris Inc. inaugure ses nouvelles installations en plein cœur de la Cité de la Biotech à Laval
By Philippe Beland October 9, 2024
Biodextris inaugure de nouvelles installations à Laval pour renforcer son expertise en développement biologique.
Biodextris Inc. inaugurates its new facilities in the heart of Laval's Biotech City
By Philippe Beland October 9, 2024
Biodextris inaugurates its new Laval facility in Biotech City, expanding its capabilities in biologics development and manufacturing.
cGMP biomanufacturing facility Laval
June 5, 2024
Discover Biodextris' new cGMP biomanufacturing and analytical facility. Check out our state-of-the-art capabilities.
More Posts

Share Posts